Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results.
A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.
About Exscientia
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005202/en/
Contact information
Investor Relations Contact:
Sara Sherman
investors@exscientia.ai
Media Contact:
Oliver Stohlmann
media@exscientia.ai
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convincing Across the Board: LR Health & Beauty Receives Yet Another Award for Innovative Beauty Product1.6.2023 08:30:00 CEST | Press release
It’s been about four months since the top seller product “LR Zeitgard Pro Cosmetic Device” has been recognized for its outstanding design. Now, another award in the “Bath and Wellness” category has brought a cheerful mood to health & beauty product providers: Zeitgard Pro may now be presented with an additional “special mention” of the German Innovation Award 2023 – proving its ability to stand out among others as a cosmetic device for home use with exceptional user-centred design and surplus value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005576/en/ LR Health & Beauty receives the German Innovation Award for the Zeitgard Pro. (Graphic: Business Wire) “This renewed recognition proves that, with Zeitgard Pro, we managed to partially revolutionise the beauty industry”, Dr Andreas Laabs, CEO of LR Health & Beauty, pointed out. “I’m delighted that the renowned jury has acknowledged our ‘All-rounders’ user-friendlines
Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals1.6.2023 08:00:00 CEST | Press release
Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.Both studies reveal that the TREM-1 pathway plays a central role in major life-threatening immune dysregulations caused by severe infections, whether it is septic shock or severe forms of COVID-19. The findings presented further validate Inotrem’s innovative approach to treat inflammatory diseases by targeting TREM-1. The two studies suggest that nangibotide, which targets TREM-1, is pathogen agnostic and has the potential to treat those very severe inflammatory conditions caused by both viral and bacterial infections. Both studies highli
Kioxia Commences Operation of Two New R&D Facilities1.6.2023 08:00:00 CEST | Press release
Kioxia Corporation today commenced operation of two new R&D facilities — the Flagship Building at the Yokohama Technology Campus and the Shin-Koyasu Technology Front — strengthening the company’s research and development capabilities in flash memory and solid-state drives (SSDs). Going forward, other R&D functions in Kanagawa Prefecture will be relocated to these new R&D hubs to improve research efficiency and promote further advancement in technological innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531006054/en/ Flagship Building at Yokohama Technology Campus (Photo: Business Wire) With the addition of the new Flagship Building, the Yokohama Technology Campus will almost double in size, allowing Kioxia to expand its capabilities in evaluating flash memory and SSD products, thereby enhancing overall product development and product quality. Equipped with environmentally-friendly facilities, the Flagship Buildi
Axelspace Announces New Management Structure1.6.2023 07:00:00 CEST | Press release
Axelspace Corporation (Head Office: Chuo-ku, Tokyo; CEO: Yuya Nakamura), a pioneer in microsatellites, announces its new management structure as of June 1, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531006007/en/ New Management Team Members: Front Row, Left to Right: Atsushi Yasuoka (Head of AxelLiner Business Division), Yuya Nakamura (CEO) , Daigo Orihara (CFO), Tatsuhiko Fukasawa (Head of AxelGlobe Business Division). Back Row, Left to Right: Yusuke Nakanishi (CSSO), Ryuichi Kokubo (Co-CTO/Information Technology), Takashi Eishima (Co-CTO/Aerospace Engineering), Makiko Hamada (CHRO), Sasaki (CISO), Yoshihiro Ota (CSO) (Photo: Business Wire) Axelspace announcement URL https://www.axelspace.com/news/20230601/ Background of Transition to New Management Structure Since our establishment in 2008 by a team of three members, our company has built a solid reputation by engaging in the development, manufacturing, and op
Preventing the Effects of Climate Change: EliTerra®, a Technological Platform Dedicated to Biosolutions That Reduce the Water Needs of Field Crops1.6.2023 05:06:00 CEST | Press release
Elicit Plant announces the acceleration of its scientific developments and its product roadmap by presenting the one and only technological platform that offers biosolutions to help prevent climatic risks for field crops by reducing their water consumption by up to 20%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005298/en/ @elicitplant On the occasion of its participation in the ChangeNOW Summit, the event for solutions for the planet that takes place from May 25 to 27, 2023 in Paris, Elicit Plant unveils EliTerra®, its technological platform and associated products that allow crops to adapt to climate change, particularly to drought. This is a world first that will boost the marketing of new Elicit Plant BioSolutions with a favorable environmental profile, following on from the success of its first product, BEST-a, which enables corn to consume up to 20% less water. "This type of solution is particularly expected